Key result
Elevated ST2 linked to ~104% higher 1-year mortality in acute heart failure.
Why the study?
ST2 signaling is involved in cardiac fibrosis and hypertrophy, but the patient-specific characteristics of ST2 in acute heart failure needed examination.
Does ST2 level predict mortality at 1 year in patients with acute heart failure?
Observational (n=346)
Does ST2 level predict mortality at 1 year in patients with acute heart failure?
Answers are grounded in this paper and cite their sources.
ST2 is a powerful prognostic biomarker in acute heart failure that provides synergistic prognostic information when combined with natriuretic peptides.
OBJECTIVES: The purpose of this study was to examine the patient-specific characteristics of the interleukin-1 receptor family member ST2 in patients with acute heart failure (HF). BACKGROUND: ST2 signaling is involved in the process of cardiac fibrosis and hypertrophy. METHODS: In all, 346 patients with acute HF had ST2 measured. Associations between ST2 and demographics, severity/type of HF, and other biomarkers were examined. Receiver-operator characteristic curves and multivariable Cox proportional hazards analyses evaluated the prognostic ability of ST2. RESULTS: The ST2 values correlated with the severity of HF (p < 0.001), left ventricular ejection fraction (r = -0.134; p = 0.014), creatinine clearance (r = -0.224; p < 0.001), B-type natriuretic peptide (r = 0.293; p < 0.001), amino terminal B-type natriuretic peptide (r = 0.413; p < 0.001), and C-reactive protein (r = 0.429; p < 0.001). ST2 was not associated with age, prior HF, or body mass index. The ST2 levels at presentation were higher among patients who died by 1 year. The area under the receiver-operator characteristic for death at 1 year was 0.71 (p < 0.001). In a multivariable Cox model containing established clinical and biochemical predictors (including natriuretic peptides), ST2 remained a predictor of mortality (hazard ratio: 2.04, 95% confidence interval: 1.30 to 3.24, p = 0.003), and was equally predictive in patients with HF and preserved or impaired systolic function. When both ST2 and natriuretic peptides were elevated, the highest rates of death were observed in cumulative hazard analysis (p < 0.001). In the presence of a low ST2 level, natriuretic peptides did not predict mortality. CONCLUSIONS: Consistent with its proposed role in a myocardial-specific response to stretch, ST2 has strong clinical and biochemical correlates in patients with acute HF. Prognostically, ST2 is powerful in acute HF and is synergistic with natriuretic peptides for this use.
No takes yet. Share an insight, caveat, or question.
Rehman et al. (2008) conducted an observational in Acute heart failure (n=346). Elevated ST2 levels vs. Low ST2 levels was evaluated on Mortality at 1 year (HR 2.04, 95% CI 1.30 to 3.24, p=0.003). Elevated ST2 levels independently predicted 1-year mortality in patients with acute heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: